LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

Incyte Corp

Gesloten

SectorGezondheidszorg

65.25 2.29

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

63.49

Max

66.09

Belangrijke statistieken

By Trading Economics

Inkomsten

-43M

158M

Verkoop

-126M

1.1B

K/W

Sectorgemiddelde

304.25

56.602

EPS

1.16

Winstmarge

15.025

Werknemers

2,617

EBITDA

-80M

257M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+15.75% upside

Dividenden

By Dow Jones

Volgende Winsten

29 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4.3B

12B

Vorige openingsprijs

62.96

Vorige sluitingsprijs

65.25

Nieuwssentiment

By Acuity

39%

61%

39 / 382 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Incyte Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 mei 2025, 20:54 UTC

Acquisities, Fusies, Overnames

PNC to Buy Private-Equity Agent Aqueduct Capital

20 mei 2025, 20:50 UTC

Winsten

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 mei 2025, 23:48 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 mei 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 mei 2025, 23:39 UTC

Marktinformatie

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 mei 2025, 23:08 UTC

Marktinformatie

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 mei 2025, 22:46 UTC

Acquisities, Fusies, Overnames

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 mei 2025, 22:45 UTC

Acquisities, Fusies, Overnames

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 mei 2025, 22:20 UTC

Top Nieuws

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 mei 2025, 22:00 UTC

Winsten

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Adj EPS 36c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q EPS 10c >JHX

20 mei 2025, 21:44 UTC

Winsten

James Hardie Industries 4Q Sales $972M >JHX

20 mei 2025, 20:52 UTC

Top Nieuws

Elon Musk to Cut Back Political Spending -- 3rd Update

20 mei 2025, 20:52 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

20 mei 2025, 20:52 UTC

Marktinformatie

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 mei 2025, 20:28 UTC

Acquisities, Fusies, Overnames

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 mei 2025, 20:23 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Adj EPS BRL2.29 >XP

20 mei 2025, 20:22 UTC

Winsten

XP 1Q Rev BRL4.345B >XP

20 mei 2025, 20:21 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 mei 2025, 20:20 UTC

Top Nieuws

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 mei 2025, 20:19 UTC

Acquisities, Fusies, Overnames

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 mei 2025, 20:11 UTC

Top Nieuws

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 mei 2025, 20:09 UTC

Winsten

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

20 mei 2025, 20:08 UTC

Winsten

Palo Alto Networks Sees FY25 Adj EPS $3.26-Adj EPS $3.28 >PANW

Peer Vergelijking

Prijswijziging

Incyte Corp Prognose

Koersdoel

By TipRanks

15.75% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 73.86 USD  15.75%

Hoogste 95 USD

Laagste 52 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Incyte Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

18 ratings

6

Buy

11

Hold

1

Sell

Technische score

By Trading Central

59.52 / 62.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

39 / 382 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation